-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recent popular reports from Yimaike★How is the protective effect of mRNA vaccines against mutant strains? The latest data gives all-round answersMedClub broke the news★Bangyao Biotech appointed Ms.
Li Fuying as Vice President & Head of the Pharmaceutical Affairs DepartmentMedClub broke the news on November 29, 2021/MedClub PR News/-- Dragonfly Therapeutics recently announced that Merck has obtained a license from Dragonfly for its second TriNKET™ immunotherapy drug candidate
.
Dragonfly's TriNKET (Tri-specific NK cell participation therapy) binds to the proteins expressed on cancer cells and NK cells
.
According to the company, the TriNKET system provides "a positive connection between cancer cells and immune system cells, including NK cells themselves, T cells, B cells and other cells that help attack and kill cancer
.
" NK cells are natural.
Part of the immune system
.
Dragonfly said its TriNKET system stimulates NK cells, which makes them aware of cancer cells and sends signals to NK cells to kill cancer cells and notify other immune cells to attack tumors
.
▲ The way the TriNKET system enhances immunotherapy (picture source: Dragonfly official website) In November 2020, Merck obtained the license for its first TriNKET™ immunotherapy candidate product from Dragonfly
.
The cooperation between Merck and Dragonfly began in October 2018, initially focusing on some solid tumor targets
.
When the deal was concluded, Merck expressed excitement about the potential of using NK cells to fight cancer
.
The partnership is progressing well.
Last year, the two companies passed a multi-target agreement to expand the scope of cooperation to develop more NK cells for immunotherapy in the fields of oncology, infectious diseases and immune diseases
.
Bill Haney, co-founder and CEO of Dragonfly, said: "Merck is a world-renowned leader in drug development in many therapeutic areas and will continue to be a strong scientific partner
.
We are very pleased that Merck is now We have implemented the second immunotherapy candidate we originally collaborated with, and are excited about our joint progress in applying Dragonfly’s TriNKET technology to a wider range of disease targets
.
"According to the agreement, Merck has exercised options.
The right to grant a global exclusive intellectual property license for its second immunotherapy candidate drug developed using the TriNKET™ technology platform, and Dragonfly has received an undisclosed payment related to this milestone
.
Dragonfly's partner Dragonfly is no stranger to working with large pharmaceutical companies
.
In addition to Merck, the company also cooperates with Bristol-Myers Squibb (BMS) and AbbVie
.
In 2017, Dragonfly and Celgene reached a five-year agreement to develop hematological tumor immuno-oncology therapies based on Dragonfly's TriNKET technology platform
.
The agreement was transferred to BMS after BMS acquired Celgene, and the results of the cooperation between the two parties continue
.
Last month, BMS obtained a license for its sixth asset from Dragonfly.
The pharmaceutical giant used the CC-96191 and CC-92328 research immunotherapy obtained from the license agreement to initiate a phase 1 trial
.
Since the initial collaboration focused on hematological malignancies in 2017, Dragonfly and BMS have agreed to two other collaborations, including oncology and neuroinflammatory goals
.
Last year, BMS obtained Dragonfly’s IL-12 (IL-12) research immunotherapy program, including its half-life prolonging cytokine DF6002
.
These are regarded as potential treatments for solid cancer and blood cancer
.
In 2019, AbbVie and Dragonfly joined forces to address autoimmune and tumor indications
.
Dragonfly's new NK cell adapter-based immunotherapy is at the core of this partnership
.
Reference materials: 1.
https:// -therapeutics-announces-merck-opt-in-of-trinket-immunotherapy-candidate-for-patients-with-solid-tumors-301430512.
html?tc=eml_cleartime Statement: The content in this article is only used to explore the frontiers of biomedicine, It does not constitute any medical guidance.
If necessary, please go to a regular hospital for treatment
.
Li Fuying as Vice President & Head of the Pharmaceutical Affairs DepartmentMedClub broke the news on November 29, 2021/MedClub PR News/-- Dragonfly Therapeutics recently announced that Merck has obtained a license from Dragonfly for its second TriNKET™ immunotherapy drug candidate
.
Dragonfly's TriNKET (Tri-specific NK cell participation therapy) binds to the proteins expressed on cancer cells and NK cells
.
According to the company, the TriNKET system provides "a positive connection between cancer cells and immune system cells, including NK cells themselves, T cells, B cells and other cells that help attack and kill cancer
.
" NK cells are natural.
Part of the immune system
.
Dragonfly said its TriNKET system stimulates NK cells, which makes them aware of cancer cells and sends signals to NK cells to kill cancer cells and notify other immune cells to attack tumors
.
▲ The way the TriNKET system enhances immunotherapy (picture source: Dragonfly official website) In November 2020, Merck obtained the license for its first TriNKET™ immunotherapy candidate product from Dragonfly
.
The cooperation between Merck and Dragonfly began in October 2018, initially focusing on some solid tumor targets
.
When the deal was concluded, Merck expressed excitement about the potential of using NK cells to fight cancer
.
The partnership is progressing well.
Last year, the two companies passed a multi-target agreement to expand the scope of cooperation to develop more NK cells for immunotherapy in the fields of oncology, infectious diseases and immune diseases
.
Bill Haney, co-founder and CEO of Dragonfly, said: "Merck is a world-renowned leader in drug development in many therapeutic areas and will continue to be a strong scientific partner
.
We are very pleased that Merck is now We have implemented the second immunotherapy candidate we originally collaborated with, and are excited about our joint progress in applying Dragonfly’s TriNKET technology to a wider range of disease targets
.
"According to the agreement, Merck has exercised options.
The right to grant a global exclusive intellectual property license for its second immunotherapy candidate drug developed using the TriNKET™ technology platform, and Dragonfly has received an undisclosed payment related to this milestone
.
Dragonfly's partner Dragonfly is no stranger to working with large pharmaceutical companies
.
In addition to Merck, the company also cooperates with Bristol-Myers Squibb (BMS) and AbbVie
.
In 2017, Dragonfly and Celgene reached a five-year agreement to develop hematological tumor immuno-oncology therapies based on Dragonfly's TriNKET technology platform
.
The agreement was transferred to BMS after BMS acquired Celgene, and the results of the cooperation between the two parties continue
.
Last month, BMS obtained a license for its sixth asset from Dragonfly.
The pharmaceutical giant used the CC-96191 and CC-92328 research immunotherapy obtained from the license agreement to initiate a phase 1 trial
.
Since the initial collaboration focused on hematological malignancies in 2017, Dragonfly and BMS have agreed to two other collaborations, including oncology and neuroinflammatory goals
.
Last year, BMS obtained Dragonfly’s IL-12 (IL-12) research immunotherapy program, including its half-life prolonging cytokine DF6002
.
These are regarded as potential treatments for solid cancer and blood cancer
.
In 2019, AbbVie and Dragonfly joined forces to address autoimmune and tumor indications
.
Dragonfly's new NK cell adapter-based immunotherapy is at the core of this partnership
.
Reference materials: 1.
https:// -therapeutics-announces-merck-opt-in-of-trinket-immunotherapy-candidate-for-patients-with-solid-tumors-301430512.
html?tc=eml_cleartime Statement: The content in this article is only used to explore the frontiers of biomedicine, It does not constitute any medical guidance.
If necessary, please go to a regular hospital for treatment
.
